Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.57 |
| ▸ | MAOA | P21397 | 5/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15540919 | 1.00 | MAOB (0.57) | MAOBMAOAHTR2AHTR2CHTR2B | |
| SCHEMBL15542347 | 1.00 | MAOB (0.57) | MAOBMAOAHTR2AHTR2CHTR2B | |
| Trifluoroacetic Acid SCHEMBL15542079 | 0.92 | MAOB (0.49) | MAOBMAOAHTR2AHTR2CHTR2B | |
| Trifluoroacetic Acid SCHEMBL15540513 | 0.92 | MAOB (0.49) | MAOBMAOAHTR2AHTR2CHTR2B | |
| SCHEMBL301325 | 0.85 | MAOB (0.55) | MAOBMAOAHTR2AHTR2CHTR2B | |
| SCHEMBL2832287 | 0.82 | MAOB (0.59) | MAOBMAOAKMT2AKDM1A | |
| SCHEMBL29302262 | 0.80 | HTR2C (0.55) | MAOBMAOAHTR2AHTR2CHTR2B | |
| SCHEMBL29880256 | 0.80 | HTR2C (0.55) | MAOBMAOAHTR2AHTR2CHTR2B | |
| SCHEMBL5998895 | 0.77 | KMT2A (0.62) | MAOBMAOAKMT2ALMNA | |
| SCHEMBL21447384 | 0.74 | LMNA (0.47) | MAOBMAOAHTR2CKMT2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| WO-2005007614-A1 | MONOAMINE OXIDASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 6011 (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | HTR2C, HTR2A, HTR5A | MAOB 575/4885MAOA 666/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.